The detailed list is here!

01 47 varieties meet the conditions

As of September 7, six provinces have clarified the implementation time of the fifth batch of national procurement, namely: Hebei, Henan, Liaoning, Xinjiang, Shanghai, and Tibet

According to CCTV news, the fifth batch of national procurement is expected to land nationwide in October this year.

At present, National Resources has conducted five rounds and six batches, involving 218 large varieties.

A few days ago, Gong Bo, director of the Pharmaceutical Price and Bidding Purchasing Department of the Shanghai Medical Insurance Bureau, told the media that there are now more than 620 clinical drugs, which can cover 80% of all purchases, of which chemical drugs account for about 490

In other words, the sixth round of national procurement will likely be based on chemical drugs, and according to past experience, consistency evaluation will still be the ticket for national procurement

According to the WeChat official account of the Spring and Autumn Period, as of September 6, 2021, there are a total of 47 chemical drugs that have a high probability of entering the sixth batch of centralized procurement, of which the most reviewed company is omeprazole sodium for injection, with 13 companies , Tenofovir fumarate tablets and Memantine hydrochloride tablets have 12 reviewed companies, ranking second

02Morecompanies have been shortlisted one after another

Omeprazole is the earliest, most mature and representative first-line drug for peptic ulcer on the market

At present, a total of 103 domestic companies hold production approvals for omeprazole sodium (40mg) for injection, and 10 pharmaceutical companies have passed the evaluation

According to data from Minai.

Tenofovir fumarate tablets, second only to omeprazole sodium injection in the number of reviewed companies, are powerful drugs for the treatment of chronic hepatitis B in adults and adolescents, developed by the American pharmaceutical company Gilead.

According to data from the public hospitals of Menet.

Although the current patent of propofol fumarate tenofovir tablets has expired, it should not be ignored that due to the patent period, there is still uncertainty about whether sitagliptin, afatinib and other varieties will be included in the national procurement

In addition, there is still some time before the official start of the sixth round of national procurement, and the competitive landscape of related products is still changing

In fact, before the last day, no one knows the final outcome

Looking back on June 22, the day before the fifth batch of national bids, the State Food and Drug Administration issued the latest drug approval documents pending information, including metoprolol tartrate tablets, ceftriaxone sodium for injection, and cefazolin for injection Another batch of enterprises of the 6 fifth batch of nationally sourced varieties including sodium passed the consistency evaluation

03 How do pharmaceutical companies respond

In the fifth round of volume procurement, some of the rules have been fixed to some extent, such as the number of selected companies and the qualifications for the selection

According to past experience, the rules for the number of selected companies will still be a maximum of 10 pharmaceutical companies, and the purchase cycle of products selected by 4 or more companies is 3 years (1 or 2 companies, 1 year; 3 companies, 2 years; 4 and above, 3 years), 80% of the shared agreed procurement volume selected from 4 and above (50% for 1 company, 60% for 2 companies, and 70% for 3 companies)
.

In terms of eligibility to be selected, it is expected to be one of the three conditions for a 1.
8 times fusing mechanism, a 50% reduction or more, and a comparable unit price of less than or equal to 0.
1 yuan
.

In the fifth round of national procurement, more than 20 companies competed for the oral regular-release dosage form of rivaroxaban with the most over-rated pharmaceutical companies, but the number was still less than the peak of 30 in the third batch, and the number of winning bids was higher than 10.
There are 2 more than 8 of the three batches
.

Regarding the impact of different levels of congestion on the company, Cyberlan’s special writer Ma Wanqi told Cyberlan: First of all, whether it is a crowded track of more than a dozen or a lonely track of two or three, we must consider moderation.
Quote, selfish and altruistic
.
Enterprises must carefully calculate the lowest affordable price and lowest game price selected in centralized procurement
.
This does not mean a negative response, but a reasonable effort to fight for it
.
In theory, three or more companies must bid for competition, and the two companies already have absolute competition
.

For the unselected companies, Ma Wanqi believes that the safest one is to try to maintain the necessary production activities.
In addition, in order to protect production orders, the company does everything possible to expand the sales of downstream channels
.
The expedient measure is to expand the channels of pharmaceutical e-commerce and out-of-hospital pharmacies.
The radical approach is to independently lower the online price, and the pragmatic approach is to plan for the access and increase in the amount of hospitals without funds under the comprehensive medical reform
.

In addition, among the many pharmaceutical companies that have jointly participated in the centralized procurement competition, some of the major varieties are included, such as Hengrui's iodixanol in the fifth batch of centralized procurement
.
The inclusion of major varieties in centralized procurement will have a greater impact on the performance of the company, and whether it is winning or losing the bid, the company's profits will face losses
.
If omeprazole sodium is included in the collection, Osaikon will also face the same dilemma
.

For such pharmaceutical companies (the leading products are included in the centralized procurement), Ma Wanqi suggests that in areas where the major products have a dominant market share, the companies should analyze the elements of successful experience and actively market them in other places with similar conditions after the centralized procurement.
At the same time, actively strive for other high volume opportunities
.
In the case of unsatisfactory efforts, you can try to manage raw materials and other fields and re-plan
.

It is worth noting that the intensity of competition in centralized procurement is also related to the variety of centralized procurement
.
For example, the fifth batch is dominated by injections, which is not only expensive, but also difficult to sell outside the hospital.
Enterprises will definitely strive for it
.

A few days ago, the state has successively released the signal of mass procurement of Chinese patent medicines and insulin mass procurement.
If related products are included in the sixth round of national procurement, the competitive situation will change
.

Attachment: List of varieties that meet the sixth batch of national procurement requirements

Image source: Yao Chunqiu